Corporate Magazine 2012 - Boehringer Ingelheim

our businessesperspectives for better health#3.3BIOPHARMACEUTICALSBIOPHARMACEUTICALS –MEDICINES FOR THE FUTUREBoehringer Ingelheim was a pioneer in the field of biotechnologyand is now one of the leading companies for the development andmanufacture of biopharmaceuticals. New biological entities (NBEs)and biosimilars are and will continue to be among the main driversof growth in the pharmaceutical industry in the mid to long term.12 3New biologic entitiesOur Biopharmaceuticals business iscommitted to supporting research anddevelopment (R&D) of new biologicalentities.Biopharmaceuticals is an integral partof in-licensing activities and identificationof potential new products. It continuouslyscouts for innovative processand product technologies. These activitiesfoster the development of cuttingedgeNBEs in the respective therapeuticareas.Boehringer Ingelheim markets thefour biopharmaceuticals actilyse®,metalyse®, imukin® and beromun®produced in cell culture or from microbialfermentation.Boehringer Ingelheim BioXcellenceWe aspire to maintain our position asone of the world’s largest contract manufacturersof biopharmaceuticals, providingthe entire production technologychain from DNA to fill and finish. Wehave brought 22 new biopharmaceuticalproducts (or NBEs) together with ourcustomers to the market (i. e. cell-linedevelopment to registered product).The contract manufacturing business ofBoehringer Ingelheim is now representedby its new brand Boehringer IngelheimBioXcellence, which stands forexcellence, quality and reliability in themarket.Our biosimilarsIn addition, we decided to expand ourcurrent Biopharmaceuticals businessfor the development and manufactureof new and innovative biopharmaceuticalsinto developing biosimilars.With our expertise and world-classtechnology, we are well-placed tocreate, develop and manufacture highqualitybiosimilars.OUR BIOPHARMACEUTICALSNETWORK1 fremont, usa2 biberach, germany3 vienna, austriaBiopharmaceuticals – medicines for the future 93